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Summary
Metabolic syndrome is associated with insulin resistance and atherosclerosis. Here, we show that deficiency of one or two
alleles of ATM, the protein mutated in the cancer-prone disease ataxia telangiectasia, worsens features of the metabolic
syndrome, increases insulin resistance, and accelerates atherosclerosis in apoE2/2 mice. Transplantation with ATM2/2
as compared to ATM+/+ bone marrow increased vascular disease. Jun N-terminal kinase (JNK) activity was increased in
ATM-deficient cells. Treatment of ATM+/+apoE2/2micewith low-dose chloroquine, an ATMactivator, decreased atheroscle-
rosis. In an ATM-dependent manner, chloroquine decreased macrophage JNK activity, decreased macrophage lipoprotein
lipase activity (a proatherogenic consequence of JNK activation), decreased blood pressure, and improved glucose
tolerance. Chloroquine also improved metabolic abnormalities in ob/ob and db/db mice. These results suggest that ATM-
dependent stress pathways mediate susceptibility to the metabolic syndrome and that chloroquine or related agents
promoting ATM activity could modulate insulin resistance and decrease vascular disease.Introduction
As many as a quarter of American adults have the metabolic
syndrome, a poorly understood condition associated with vas-
cular disease. Total mortality and death from vascular disease
are increased in metabolic syndrome (Malik et al., 2004). The
criteria for diagnosing the syndrome (hypertriglyceridemia, low
HDL cholesterol, hypertension, hyperglycemia, and excess
visceral adiposity) are associated with insulin resistance.
Insulin resistance is widely held to explain the association
between the metabolic syndrome and vascular disease. How-
ever, it is possible that insulin resistance does not directly cause
atherosclerosis (Semenkovich, 2006). Insulin resistance is not
related to vascular lesions after correcting for glucose tolerance
(Howard et al., 1996). Pioglitazone, an insulin sensitizer, does
not decrease cardiovascular events in patients with insulin resis-
tance (Dormandy et al., 2005). Studies directly addressing the
role of macrophage insulin resistance in atherosclerosis are
conflicting (Baumgartl et al., 2006; Han et al., 2006). As opposed
to representing a unique entity, the metabolic syndrome may
simply reflect the cumulative contribution of its components to
atherosclerotic risk (Kahn et al., 2005).
An alternative view is that atherosclerosis, insulin resistance,
and the component clinical features of the metabolic syndrome
share a common unifying mechanism. One hint regarding a po-
tential common etiology comes from the rare autosomal reces-
sive disease ataxia telangiectasia (Shiloh and Kastan, 2001).
Ataxia telangiectasia is characterized by cerebellar ataxia, skin
and eye telangiectasias, malignancies, and immune deficiency,
but affected children also have impaired growth and glucose
intolerance suggestive of insulin resistance (Bar et al., 1978;CELL METABOLISM 4, 377–389, NOVEMBER 2006 ª2006 ELSEVIER INSchalch et al., 1970; Blevins and Gebhart, 1996). The disease
is caused by deficiency of ATM (Ataxia Telangiectasia Mutated)
(Savitsky et al., 1995), a protein kinase that plays a key role in
responding to DNA damage (Kastan and Bartek, 2004). ATM
contains a PI 3-kinase-like domain but does not possess detect-
able lipid kinase activity; it responds to DNA damage by phos-
phorylating itself, p53, and other proteins (Canman et al., 1998;
Kim et al., 1999; Bakkenist and Kastan, 2003). Despite the lack
of PI 3-kinase activity, an integral mediator of insulin action,
ATM participates in insulin signaling (Yang and Kastan, 2000)
through mechanisms that are not understood. ATM may also
be related to vascular disease. ATM heterozygosity, present in
0.5 to 2% of humans, increases risk of death from ischemic
heart disease (Su and Swift, 2000).
The potential involvement of ATM in insulin signaling and
ischemic heart disease led us to test the hypothesis that ATM
suppresses vascular disease in mice. The results indicate that
ATM deficiency causes insulin resistance, resembles the meta-
bolic syndrome, and increases vascular disease. Activation of
ATM with low-dose chloroquine decreases features of the
metabolic syndrome including atherosclerosis.
Results
High-fat-fed ATM-deficient mice have a phenotype
resembling the metabolic syndrome
We moved the ATM mutation (Herzog et al., 1998) into the
apoE null model of atherosclerosis. ATM haploinsufficiency had
no effect on breeding or viability in apoE null mice, but ATM2/2
apoE2/2 animals were born at decreased frequency (9% versus
the expected 25% in ATM+/2apoE2/2 X ATM+/2apoE2/2C. DOI 10.1016/j.cmet.2006.10.002 377
A R T I C L EFigure 1. Metabolic effects of ATM deficiency on weight, adiposity, blood pressure, glucose tolerance, and insulin tolerance
Metabolic effects of ATM deficiency on weight (A), adiposity (B–C), blood pressure (D), glucose tolerance (E), and insulin tolerance (F). Measurements were performed at
baseline and after initiating Western diet feeding. Open bars are ATM+/+, solid bars are ATM+/2, hatched bars are ATM2/2. All mice were apoE2/2.
A) Body weights for 12 ATM+/+, 17 ATM+/2, and 4 ATM2/2 mice.
B) Body fat analysis after 8 weeks of Western diet feeding for ATM+/+, ATM+/2, and ATM2/2 mice. *p < 0.05 versus the other two groups.
C) Whole mounts of visceral fat pads removed en bloc from age-matched ATM+/+, ATM+/2, and ATM2/2 mice.
D) Systolic blood pressure (SBP) and diastolic blood pressure (DBP) after 8 weeks of Western diet feeding in ATM+/+, ATM+/2, and ATM2/2 mice.
*p < 0.001 and #p < 0.05 versus the other two groups.
E) Intraperitoneal glucose tolerance testing for 9 ATM+/+ and 10 ATM+/2 littermate mice after 8 weeks on Western diet. The inset represents the incremental area under the
glucose curve (AUC).
F) Intraperitoneal insulin tolerance test (ITT) for the mice of (D). *p < 0.05 in (D) and (E). All results are presented as mean 6 SEM.matings) due to fetal loss in utero. When ATM2/2apoE2/2 mice
were born, they were viable and resembled ATM+/2apoE2/2
mice. There was no difference in total body weight between
ATM+/+, ATM+/2, and ATM2/2 mice in the apoE2/2 model over
8 weeks of eating a Western diet (Figure 1A), but adiposity was in-
creased in ATM deficient mice (Figure 1B). This was due in part to
increased intra-abdominal fat (Figure 1C) and occurred despite
the absence of effects of genotype on metabolic rate measured
by indirect calorimetry or food intake (data not shown). Consis-
tent with the adiposity data, adiponectin levels were decreased
in ATM deficient mice (Figure S1 in the Supplemental Data
available with this article online). Blood pressure was elevated
in ATM-deficient apoE2/2 mice on the Western diet (Figure 1D).
Western-diet-fed ATM+/2apoE2/2 mice were glucose intoler-
ant (Figure 1E) and insulin resistant (Figure 1F) compared to
ATM+/+apoE2/2 littermates. Effects on adiposity, blood pres-378sure, and glucose metabolism were seen in both genders and
replicated in several littermate cohorts. Thus, the ATM+/2 geno-
type, which may be present in 0.5 to 2% of human populations
(Su and Swift, 2000), models three components of the metabolic
syndrome in apoE null mice: increased adiposity, elevated blood
pressure, and glucose intolerance.
Fasting cholesterol, triglycerides, and free fatty acids were not
significantly affected by genotype at baseline (on chow diet) or
after 3 or 8 weeks of Western diet (Figure 2A). Fasting glucose
and insulin levels increased with Western diet feeding and
glucose was highest in ATM2/2 animals (Table S1). Lipoproteins
were not affected by genotype (data not shown). Atherosclero-
sis after 8 weeks on the Western diet was increased in ATM-
deficient mice inversely based on gene dosage (Figure 2B).
Representative aortas are shown in Figure 2C. The same effects
were seen in both males and females (Figure S2).CELL METABOLISM : NOVEMBER 2006
ATM and metabolic syndromeFigure 2. Lipid chemistries and atherosclerosis in
apoE2/2 mice with different ATM genotypes after
Western diet feeding for 8 weeks
A) Data for fasting cholesterol (top panel), triglycer-
ides (middle panel) and nonesterified fatty acids
(NEFA, bottom panel).
B) Atherosclerosis data as assayed by the en face
technique for the mice of (A). The p value indicates
the overall results of the Kruskal-Wallis test. In post-
tests, ATM+/+ mice showed significant differences
(p < 0.05) as compared to each of the other two
genotypes.
C) Representative aortas for each of the three
genotypes.Insulin resistance in ATM deficiency
Previous studies have suggested that insulin resistance is pres-
ent in ATM deficiency (Bar et al., 1978; Schalch et al., 1970;
Blevins and Gebhart, 1996; Yang and Kastan, 2000), but formal
assessment of this condition is lacking. In hyperinsulinemic-
euglycemic clamp experiments conducted in littermates eating
the high-fat Western diet, endogenous glucose production was
suppressed by insulin in ATM+/+apoE2/2 but not ATM+/2apoE2/2
mice (Figure 3A). Consistent with the presence of hepatic insu-
lin resistance, IRS-2-associated PI 3-kinase activity was de-
creased in the livers of insulin-stimulated high-fat-fed ATM+/2
mice (Figure 3B). Phosphorylated Akt, a target of PI 3-kinase,
was also decreased in the livers of the same insulin-stimulated
mice (Figure 3C), consistent with the presence of hepatic insulin
resistance in high-fat-fed ATM+/2 mice. Insulin-induced phos-CELL METABOLISM : NOVEMBER 2006phorylation of Akt at both Ser 473 and Thr 308 was decreased
in ATM-deficient livers (Supplemental Figure 3) of apoE null
mice as well as low-density lipoprotein receptor null mice, an-
other model shown to have increased insulin resistance with
ATM deficiency (see Figure 6 below).
Impaired insulin signaling was present in other ATM-deficient
cell types. Decreased IRS expression causes insulin resistance
(Kido et al., 2000). mRNA as well as protein levels for IRS-2 were
decreased in macrophages elicited from ATM-deficient mice
(Figure 3D). Activated Akt and the related kinases p38 and
ERK were decreased in the aortas of young chow-fed ATM-
deficient mice (Figure 3E). Insulin signaling can be disrupted
by a serine phosphorylation at residue 307 of IRS-1. Aortic
tissue from ATM2/2 mice had the highest level of IRS-1 Ser
307 phosphorylation, ATM+/2 aortas were intermediate, and379
A R T I C L EFigure 3. Insulin sensitivity and insulin-related signaling in tissues of apoE2/2 mice with various ATM genotypes
A) Hyperinsulinemic euglycemic clamp data in ATM+/+ (open bars) and ATM+/2 (solid bars) mice. Data are expressed as mean 6 SEM for four animals of each genotype.
*p < 0.05. The difference in glucose infusion rate was of borderline significance (p = 0.08).
B) IRS-2 (liver) and IRS-1(skeletal muscle)-associated PI 3-kinase activity determined in post-clamp tissues of ATM+/+ (open bars) and ATM+/2 (solid bars) mice by ELISA
after immunoprecipitation of the IRS-containing complex. *p < 0.01.
C) Western blot analysis of phospho-Akt (Ser473) in postclamp liver of ATM+/+ and ATM+/2 mice.
D) Quantitative RT-PCR determination of IRS-2 expression in thioglycollate-elicited macrophages from ATM+/+ (open bars), ATM+/2 (solid bars), and ATM2/2 (hatched
bars) mice. Data are expressed relative to GAPDH expression (mean6 SEM). *p < 0.001. The inset shows representative Western blots of IRS-2 protein, which is frequently
detected as a doublet, for each genotype. We also analyzed IRS-2 mRNA expression in liver but did not detect consistent genotype effects (data not shown).
E) Representative Western blots of aortic content of phospho-p38, phospho-Akt, and phospho-ERK with total p38 protein shown in the bottom panel. The same results
were seen in several samples. Young, chow-fed mice without atherosclerotic lesions were used for the aortic analyses.
F) IRS-1 phosphorylation at position Ser307, normalized to total IRS-1 protein, as acquired by densitometric image analysis of the Western blots. *p < 0.001 versus ATM+/+.
#p < 0.01 versus ATM+/2. Data are presented as mean 6 SEM, and the same results were observed in two or more independent experiments for each assay.
G) Phospho-JNK, normalized to total JNK, in whole aorta as determined by quantitative Western blot analysis. The inset shows representative blots of tissue from mice of
each genotype. *p < 0.05 versus ATM+/+, **p < 0.01 versus ATM+/+, #p < 0.05 versus ATM+/2.
H) Analysis of phospho-JNK in vascular smooth muscle cells cultured from ATM+/+apoE2/2 mice. Primary aortic smooth muscle cells were transfected with an anti-ATM oli-
gonucleotide (hatched bar), a control oligonucleotide (solid bar) or the vehicle ethoxylated polyethylenimine solution only (open bar). Cells were assayed by ELISA for phospho-
JNK and total JNK as measured in U/ml/well of a 96-well plate. The bar graph shows phospho-JNK normalized to total JNK of wells with the same treatment condition. *p < 0.05.ATM+/+ vessels lowest (Figure 3F). Jun N-terminal kinase (JNK)
phosphorylates IRS-1 at serine 307 to cause insulin resistance.
JNK was activated in aortas in proportion to the degree of ATM380deficiency (Figure 3G). When cultured aortic smooth muscle
cells were treated with a morpholino antisense oligonucleotide
to ATM, JNK activity was increased (Figure 3H), providing directCELL METABOLISM : NOVEMBER 2006
ATM and metabolic syndromeFigure 4. Atherosclerosis in apoE2/2 mice after transplantation of bone marrow from either ATM+/+apoE2/2 or ATM2/2apoE2/2 mice and analysis of macrophages
A) Quantification of atherosclerosis at the aortic origin in mice reconstituted with ATM+/+ (n = 6, open bar) or ATM2/2 (n = 7, hatched bar) bone marrow after 8 weeks of
Western diet feeding. *p < 0.05.
B) Representative aortic origin cross-sections of mice from (A).
C) Densitometric analysis of Western blots for phospho-JNK normalized to total JNK in peritoneal macrophages from mice transplanted with ATM+/+ (open bar) or ATM2/2
(hatched bars). n = 3 for each genotype. *p < 0.05. The insets show three Western blots per genotype of phospho-c-Jun (the major substrate of activated JNK) from the
same cells.
D) Quantitative RT-PCR determination of Egr-1 expression in thioglycollate-elicited macrophages from ATM+/+ (open bar) and ATM2/2 (hatched bar)-transplanted mice.
Data are expressed relative to L32 expression. *p < 0.05.
E)Quantitative RT-PCR determination of LPL expression in thioglycollate-elicited macrophages from ATM+/+ (open bar) and ATM2/2 (hatched bar)-transplanted mice. Data
are expressed relative to L32 expression. *p < 0.05.evidence that interfering with ATM expression induces JNK
activity, a mediator of insulin resistance. Consistent with the
presence of systemic insulin resistance, JNK activity (as well
as phosphorylation of c-Jun, the major JNK substrate) was
also increased in adipose tissue, skeletal muscle, and liver of
ATM-deficient mice (Figure S4).
ATM-deficient bone marrow-derived cells increase
atherosclerosis
Since macrophages initiate early atherosclerotic lesions, ATM+/+
apoE2/2mice were transplanted with bone marrow from ATM+/+
apoE2/2 or ATM2/2apoE2/2 animals. After 4 weeks of recovery
(and verification of engraftment), animals were started on the
Western diet, then lesions were quantified by lipid staining of
the aortic origin 8 weeks later. Lesions were 80% larger in
animals transplanted with ATM null marrow (Figure 4A). Repre-
sentative photomicrographs of lesions are shown in Figure 4B.
There was no marrow genotype effect on fasting cholesterolCELL METABOLISM : NOVEMBER 2006(1110 6 69 mg/dl for ATM+/+ versus 1183 6 74 mg/dl for
ATM2/2), glucose, or triglycerides. ATM deficiency was associ-
ated with increased JNK activity (Figure 4C) and increased phos-
phorylation of c-Jun in ATM2/2macrophages (insets, Figure 4C).
JNK, by increasing activity of the transcription factor AP-1,
increases expression of early growth response gene-1 (Egr-1)
and lipoprotein lipase (LPL). mRNA levels for both Egr-1
(Figure 4D) and LPL (Figure 4E) were increased several-fold in
ATM null macrophages from transplanted mice. Macrophages
isolated from littermate mice not subjected to transplantation
also had increased JNK activity and LPL enzyme activity with
ATM deficiency (data not shown).
Since JNK appears to be involved in the vascular disease of
ATM deficiency, it should be induced with Western diet feeding
in apoE null mice. Western diet-fed but not chow-fed apoE null
mice (wild-type at the ATM locus) showed a robust increase in
activated aortic JNK (Figure S5A). Phosphorylated ATM is diffi-
cult to detect in mouse tissues, but detection is straightforward381
A R T I C L EFigure 5. Effect of low-dose chloroquine treatment
on serum lipids and atherosclerosis in ATM+/+
apoE2/2 mice
Animals were treated with twice weekly intra-
peritoneal injections of chloroquine (CHQ) at
3.5 mg/kg per injection for a total weekly dose of
7.0 mg/kg.
A) Fasting serum lipids at baseline on chow diet and
following Western diet feeding for 4 and 8 weeks in
CHQ- and saline-treated mice.
B) Quantitative analysis of atherosclerotic surface
area in the aortas of CHQ- (n = 25) or saline-treated
mice (n = 21). Data are presented as mean 6 SEM.
C) Representative aortas for each treatment.for p53, a major substrate of activated ATM. Activated p53 was
also detected in the aortas of Western diet-fed but not chow-fed
apoE null mice (Figure 5B), consistent with ATM activation. This
finding could reflect a protective response to limit vascular
disease or implicate the ATM-p53 axis in atherogenesis.
Reduction of metabolic abnormalities with
the ATM-activating drug chloroquine
To determine if promoting ATM activity decreases vascular dys-
function, we treated mice with the antimalarial drug chloroquine,
which activates ATM in cultured cells (Bakkenist and Kastan,
2003). Administration of low-dose chloroquine (determined in
dose response experiments) to mice resulted in p53 activation
in fat and muscle (Figure S6) as well as liver, aorta, and cultured
macrophages (data not shown). ATM+/+apoE2/2 mice were
randomized to treatment with saline injections or 3.5 mg/kg of
chloroquine administered by intraperitoneal injection twice
a week (a total weekly dose of 7.0 mg/kg) and fed a Western
diet. After 8 weeks, chloroquine had no effect on body weight382or metabolic rate determined by indirect calorimetry (data not
shown).
Activation of the ATM-p53 axis by low-dose chloroquine also
had no effect on serum lipids (Figure 5A) but decreased athero-
sclerosis. Lesion area was 37% less at the arch, 25% less at the
thoracic aorta, and 25% less at the abdominal aorta in chloro-
quine-treated mice (Figures 5B and 5C). Equal numbers of
males and females were studied and chloroquine was effective
in both genders.
Chloroquine also improved metabolic abnormalities in estab-
lished models of insulin resistance. At the same dose that de-
creased atherosclerosis in apoE null mice, chloroquine lowered
both fasting and fed glucose levels (Figure 6A) as well as fasting
insulin levels (13,3606996 pg/ml for chloroquine versus 16,8106
1120 for saline, p < 0.05) in ob/ob mice and fed glucose levels in
db/db mice (Figure 6B). ATM deficiency also affected glucose
metabolism in other mouse models. In aged (>1 year old) litter-
mate low-density lipoprotein receptor (LDLR) mice, heterozy-
gous ATM deficiency resulted in impaired glucose toleranceCELL METABOLISM : NOVEMBER 2006
ATM and metabolic syndromeFigure 6. Effect of low-dose chloroquine treatment in ob/ob and db/db mice and effect of the ATM mutation on mice with the LDLR null or C57BL/6 background
A) Fasting and fed blood glucose levels in male ob/ob mice after CHQ treatment as described in Figure 5 (7.0 mg/kg/week). Baseline (hatched bars) represents average
blood glucose level of 12 ob/ob mice before assigning the mice to either CHQ (open bars) or saline treatment (closed bars). Fasting blood glucose with CHQ was lower
compared to baseline and compared to the vehicle (saline) controls 3 weeks after initiation of the treatment. *, #p < 0.01. Fed blood glucose levels on two different days were
lower as compared to baseline (^p < 0.05, #p < 0.01) and lower than the saline-treated controls (*p < 0.05). Saline-treated controls did not differ from baseline in the fasting
or fed state.
B) Blood glucose in male db/db mice treated with either CHQ or saline. Baseline (hatched bar) represents the average fed blood glucose levels of the 12 db/db mice. CHQ
treated db/db mice (open bars) had lower blood glucose levels as compared to the baseline (*p < 0.01 and p < 0.05, respectively) and as compared to the saline-treated
controls (closed bars) (^, #p < 0.01 and p < 0.05, respectively) on two different days of the treatment period. The saline-treated animals did not differ from baseline. All
results are presented as mean 6 SEM.
C) Intraperitoneal glucose tolerance testing for 12 aged ATM+/+ (broken line) and 11 aged ATM+/2 (solid line) (>1 year of age) littermate mice on the LDLR null background
eating a chow diet. The inset represents the incremental area under the glucose curve (AUC).
D) Intraperitoneal insulin tolerance test (ITT) for the mice of (D).
E) Intraperitoneal glucose tolerance testing for 8 ATM+/+ (broken line) and 8 ATM+/2 (solid line) littermate mice on a C57BL/6 background after 4 weeks on Western diet.
The inset represents the incremental area under the glucose curve (AUC). *p < 0.05 in (C), (D), and (E). All results are presented as mean 6 SEM.(Figure 6C) and resistance to glucose lowering by insulin (Fig-
ure 6D). Western diet feeding of ATM+/2 and littermate ATM+/+
mice in a wild-type C57BL/6 background also produced greater
glucose intolerance in the ATM heterozygotes (Figure 6E). These
data suggest that increasing ATM activity in models other than
apoE null mice decreases insulin resistance.
Several lines of evidence were pursued to investigate the
ATM-dependence of the chloroquine effect. In vivo chloroquine
treatment decreased LPL enzyme activity (Figure 7A) and phos-CELL METABOLISM : NOVEMBER 2006pho-JNK activity (Figure 7B) in peritoneal macrophages from
ATM+/+ mice but had no effect in ATM null macrophages. Chlo-
roquine treatment lowered systolic pressure by 9 mm Hg in
ATM+/+ mice as compared to saline-treated ATM+/+ mice
(Figure 6C, top panel). There was no effect of chloroquine in
the ATM-deficient animals (right side of panels in Figure 6C).
Chloroquine improved glucose tolerance in Western diet-fed
ATM+/+apoE2/2 mice (Figure 6D, top panel) but not ATM2/2
apoE2/2mice (Figure 6D, bottom panel). The glycemic response383
A R T I C L EFigure 7. ATM dependence of chloroquine effects on metabolic parameters and the activity of phospho-JNK in apoE2/2 mice
A) Changes in LPL activity in thioglycollate-elicited macrophages obtained from ATM+/+ (open bar) and ATM2/2 (solid bar) mice (nR 3 for each) that were treated system-
ically with chloroquine and the results compared to animals treated with saline. *p < 0.05.
B) Phospho-JNK in lysates of thioglycollate-elicited macrophages obtained from ATM+/+ (open bar) and ATM2/2 (solid bar) mice (n = 5 for each) that were treated system-
ically with CHQ and the results compared to animals treated with saline. *p < 0.01.
C)Blood pressure after 8 weeks of Western diet feeding. Systolic blood pressure (SBP, top panel) and diastolic blood pressure (DBP, bottom panel) are shown for 28 CHQ-
treated (open bars) and 23 saline-treated (solid bars) mice with the ATM+/+ genotype on the left sides of panels. Results are shown for 6 CHQ-treated and 5 saline-treated
mice with the ATM2/2 genotype on the right sides of the panels. *p < 0.05 versus saline. As expected, both SBP and DBP were significantly higher in ATM2/2 mice.
D) Intraperitoneal glucose tolerance test results for CHQ- and saline-treated ATM+/+apoE2/2 (top panel, n R 12 mice in each group) and ATM2/2apoE2/2 mice
(bottom panel, n = 4 mice in each group) after chronic Western diet feeding. The inset shows the incremental area under the glucose curve (AUC). CHQ lowered the
AUC in ATM+/+apoE2/2 mice but not in the ATM2/2apoE2/2 mice. *p < 0.05.
E) LPL enzyme activity of thioglycollate-elicited macrophages obtained from ATM+/+ (open bars) and ATM2/2 (solid bars) mice (n = 3 for each) that were treated in culture
with a JNK inhibitor (SP600125) or vehicle (DMSO). *p < 0.01 vehicle-treated versus ATM+/+. #p < 0.01 vehicle-treated versus ATM2/2 treated with SP600125. For all panels,
data are presented as mean 6 SEM.
F) A model depicting potential relationships between CHQ, ATM, JNK activation, insulin resistance, and atherosclerosis.in the ATM null mice was atypical, showing a late drop in glucose
levels that could reflect abnormally delayed release of insulin.
Although not a focus of this work, ATM+/+ pancreatic islets
manifested a prominent induction of ATM expression with lipid
loading (data not shown), suggesting a role for ATM in b cell384homeostasis. Taken together, these data suggest that several
of the effects of chloroquine in this model are ATM-dependent.
Since JNK is the proposed link between ATM and its down-
stream effects, we inhibited JNK activity in elicited macro-
phages (using the compound SP600125) and assayed LPLCELL METABOLISM : NOVEMBER 2006
ATM and metabolic syndromeenzyme activity. Elevated LPL activity in ATM null cells was de-
creased to control levels with JNK inhibition (Figure 7E, open
bars). Increased LPL activity was also reduced to control levels
with SP600125 treatment in ATM+/2 macrophages (data not
shown). These results are consistent with a role for JNK in the
mediation of some of the effects induced by ATM deficiency in
this model. A diagram indicating how chloroquine activation of
ATM affects JNK activity, insulin resistance, and atherosclerosis
is shown in Figure 7F.
Discussion
Metabolic syndrome is common and potentially lethal. Treat-
ment is limited to therapies for the disparate components of
the syndrome: hypertension, hyperglycemia, obesity, and dysli-
pidemia. In the current work, we demonstrate that apoE null
mice with ATM haploinsufficiency have accelerated features of
the metabolic syndrome. They are insulin resistant with in-
creased JNK activity. Treatment of ATM+/+ mice in the apoE
null background with low doses of the ATM-activating drug
chloroquine lowers blood pressure, improves glucose toler-
ance, suppresses JNK activity, and decreases diet-induced
atherosclerosis. Chloroquine also improves metabolic abnor-
malities in ob/ob and db/db mice. Collectively, these findings
suggest that modulation of ATM-dependent signaling with
chloroquine represents a potential treatment for the metabolic
syndrome.
Our atherosclerosis data are consistent with a recent study
showing increased lesions in chow-fed ATM+/2 as compared
to ATM+/+ mice in the apoE null model (Wu et al., 2005). Lesional
effects in that report were attributed to higher cholesterol levels
measured at a single time point in ATM+/2apoE2/2 animals eat-
ing chow. Cholesterol levels were modestly higher in ATM+/2
apoE2/2 as compared to ATM+/+apoE2/2 mice in the current
study on a chow diet at baseline but this difference was not
significant (Figure 2A), and we did not detect significant geno-
type effects on serum cholesterol at subsequent time points
(3 and 8 weeks) in mice fed a Western diet (Figure 2A). These
results suggest that in the setting of a Western diet, events
independent of differences in cholesterol promote atherogene-
sis in ATM deficiency.
ATM has been linked to insulin signaling in certain cell types
(Bar et al., 1978; Yang and Kastan, 2000) and it has been sug-
gested that individuals heterozygous for ATM deficiency are
prone to cardiovascular disease (Su and Swift, 2000; Y. Shiloh,
personal communication). No mechanistic insights have existed
to explain these associations. The current data extend previous
observations and elucidate novel mechanisms linking ATM
and signaling pathways known to affect atherogenesis and
responses to insulin. JNK (Evans et al., 2002) is an attractive
potential mediator of the metabolic effects caused by ATM de-
ficiency. Activated JNK phosphorylates cJun, which combines
with cFos to form the AP-1 transcription factor complex. Activa-
tion of both JNK and the AP-1 pathway are present in the brains
of ATM-deficient mice (Weizman et al., 2003). JNK activity is
linked to several features of the metabolic syndrome. JNK activ-
ity is increased by endoplasmic reticulum stress caused by obe-
sity (Ozcan et al., 2004). Mice deficient in JNK1, one of three iso-
forms, are protected from obesity and insulin resistance
(Hirosumi et al., 2002). Expressing wild-type JNK decreases
and expressing dominant negative JNK increases insulin sensi-CELL METABOLISM : NOVEMBER 2006tivity in liver (Nakatani et al., 2004). JNK decreases the expres-
sion of adiponectin, which has insulin sensitizing effects, in
adipocyte cell lines (Kim et al., 2005). Treatment of animals
with a JNK inhibitor enhances insulin sensitivity (Kaneto et al.,
2004). JNK interferes with insulin signaling by phosphorylating
serine residue 307 on IRS-1 (Lee et al., 2003). Inhibition of
JNK activity and genetic JNK2 deficiency in apoE null mice
decreases atherosclerosis (Ricci et al., 2004).
We now show that genetic deficiency of ATM increases JNK
activity in multiple tissues (Figures 3 and 4, and S4) and is
associated with systemic insulin resistance (Figure 3), serine
307 phosphorylation of IRS-1 (Figure 3), and accelerated athero-
sclerosis (Figure 2). Disruption of ATM expression in cultured
cells induces JNK (Figure 3), and transplantation of mice with
ATM-deficient marrow increases atherosclerosis in the setting
of macrophages with increased JNK activity (Figure 4). JNK in-
duces Egr-1 (Gururajan et al., 2005) and LPL (Maingrette and
Renier, 2003) and both were increased in ATM-deficient macro-
phages (Figure 4). Egr-1 has been shown to promote athero-
sclerosis in apoE null mice (Harja et al., 2004) and a proathero-
genic role for LPL in macrophages has been demonstrated
(Babaev et al., 1999), thus providing a mechanism for increased
atherosclerosis. Treatment with chloroquine suppresses JNK
activity and LPL activity in macrophages from ATM+/+ but not
ATM2/2 mice (Figures 7A and 7B), and increased LPL activity
in ATM-deficient macrophages is normalized by JNK inhibition
(Figure 7E), suggesting that ATM-dependent suppression of
JNK mediates susceptibility to metabolic effects.
ATM signals to the p53 tumor suppressor gene product
(Kastan and Bartek, 2004). Interestingly, p53 has been reported
to reduce atherogenesis in mouse models (Guevara et al., 1999;
van Vlijmen et al., 2001), to inactivate JNK (Lo et al., 2004), and
to mediate an antioxidant function (Sablina et al., 2005), poten-
tially relevant to ATM and the metabolic syndrome. Markers of
oxidative stress are increased in mice and humans with ATM
deficiency (Rybczynska et al., 1996; Reichenbach et al., 1999)
and inhibition of oxidative stress pathways decreases reactive
oxygen species and improves metabolic syndrome in obese
mice (Furukawa et al., 2004).
Sporadic observations in the literature are consistent with the
effects of chloroquine described here. Chloroquine has been
reported to improve insulin resistance by inhibition of insulin
degradation (Blazar et al., 1984), increased affinity of the insulin
receptor (Sorimachi et al., 1987) and increased insulin secretion
(Asamoah et al., 1990), some of which may reflect a global
increase in insulin signaling induced by ATM activation. There
are no reports of chloroquine use in the metabolic syndrome,
but a single hyperinsulinemic-euglycemic clamp study in pa-
tients with type 2 diabetes showed that high dose chloroquine
(1000 mg/day) decreased insulin resistance (Powrie et al.,
1991). Other features of the metabolic syndrome such as hyper-
tension (Anigbogu et al., 1993) may also be affected by high
dose chloroquine. Chloroquine decreases smooth muscle cell
proliferation (Hauss et al., 1979), which could be consistent
with activation of the ATM-p53 pathway leading to cell cycle
inhibition. None of these prior unconnected reports provided
mechanistic insights as to why chloroquine might affect meta-
bolic pathways. We explored this relationship because the
loss of ATM worsens metabolic parameters in apoE null mice
and we previously found that chloroquine can activate the
ATM kinase (Bakkenist and Kastan, 2003). The convergence385
A R T I C L Eof these observations allowed us to demonstrate the ATM-
dependence of many of the metabolic effects of chloroquine,
a dependence not previously suspected.
In summary, ATM deficiency is a potential mechanism contrib-
uting to development of the metabolic syndrome. Our results
provide proof of principle that modulating ATM-dependent
signaling with low doses of chloroquine, comparable to w40




Protocols were approved by the Washington University Animal Studies Com-
mittee. The ATM-deficient mice carry a neo gene to interrupt exon 57 and
replace exon 58 of ATM (Genbank #U55702), deleting a region that is also
deleted in a number of individuals with ataxia telangiectasia. Originally in
a mixed genetic background (C57BL/6 and 129Sv), these mice have been
backcrossed with BL/6 mice for >6 generations. These backcrossed ATM+/2
mice were intercrossed to obtain ATM deficient littermates or bred with apoE
null or LDLR null mice in the C57BL/6 background. Multiple different breeding
pairs were utilized to generate littermates for experiments. Animals were gen-
otyped at the ATM locus using a forward wild-type primer (50-AAGATGCTGT
CATGCAGCAGGTCTTCCAGA-30), a reverse neo-specific primer (50-AATTCT
CTAGAGCTCGCTGATCAGCCTCGA-30), and a reverse wild-type primer (50-
TTGTCCAACCTGAGAGTGGCAATCCATAGC-30). Mice housed in a specific
pathogen-free barrier facility were weaned at the age of 3 weeks to standard
mouse chow providing 6% calories as fat. For most experiments, sex-
matched animals at 6–8 weeks of age were started on a Western-type diet
containing 0.15% cholesterol providing 42% calories as fat (TD 88137, Har-
lan, Madison, WI). For the chloroquine experiments, mice were treated with
either chloroquine diphosphate (Sigma, St. Louis, MO) in 0.9% saline or saline
alone administered at 7 mg/kg body weight per week after a loading dose of 7
mg/kg. Two month old male db/db (Leprdb) and ob/ob (Lepob) mice were
purchased from Harlan (Indianapolis, IN) and the Jackson Laboratory (Bar
Harbor, ME), respectively.
Analytical procedures
Cholesterol, triglycerides, and nonesterified fatty acids (NEFA) were assayed
as described (Li et al., 2000) following a 4 hr fast. For glucose tolerance and
insulin tolerance tests, mice were fasted and injected with 10% D-glucose
(1 g/kg) or human regular insulin (0.75 units/kg body weight, Eli Lilly and
Co., Indianapolis, IN) in procedures separated by at least 1 week. Tail vein
blood (5–10 ml) was assayed for glucose at 0, 30, 60, and 120 min. Blood
glucose was assayed using a glucose meter (Hemocue, Mission Viejo, CA;
or Becton Dickinson, San Jose, CA). The area under the glucose and insulin
curves (AUC) during the OGTT and ITT were calculated using the formula:
0.25 (fasting value) + 0.5 (1/2 hr value) + 0.75 (1 hr value) + 0.5 (2 hr value)
(Haffner et al., 1986). Body composition was performed on anesthetized,
living mice by dual energy X-ray absorptiometry (PIXImus, GE Corporation).
Atherosclerosis quantification
Atherosclerosis was measured using the en face or aortic origin technique
(Semenkovich et al., 1998). For the former, pinned aortas were imaged with
a digital camera and analyzed by using an image-processing program. The
percentage of involvement of the intimal surface area is reported for the
arch (encompassing the surface from the aortic valve to the left subclavian
artery), the thoracic aorta (extending to the final intercostal artery), and the
abdominal aorta (to the ileal bifurcation). For the aortic origin technique,
mean lesion size for each animal was quantified by the degree of lipid staining
of cross-sections of aortic tissue as described (Semenkovich et al., 1998).
Anesthetized mice were exsanguinated, the heart and aortic arch were per-
fused, then tissues were removed en bloc and frozen immediately in tissue
freeze medium. For each sample, 64 sections were made on a cryostat begin-
ning just caudal to the aortic sinus and extending into the proximal aorta at 10
mm intervals. Slides were fixed with 60% isopropanol and stained with oil red
O. For each heart, lesions in eight sections at 80 mm intervals were quantified
using image analysis software calibrated using a hemocytometer grid.386Macrophage analysis
Macrophages were isolated as described (Febbraio et al., 2000). Briefly, mice
were injected intraperitoneally with a 4% solution of thioglycollate media
(Sigma, St. Louis, MO) on day 1. On day 5, peritoneal macrophages were iso-
lated, washed, counted, and plated in DMEM plus 10% FBS. Macrophages
were subsequently harvested at various times to isolate RNA or protein,
respectively, according to standard methods. For LPL assays, cells were
fed on day 6. On day 7, cells were washed and incubated in DMEM plus
0.5% BSA for 4 hr, followed by incubation with 10 U/ml heparin, collection
of media, and subsequent determination of LPL activity as described (Cole-
man et al., 1995). For JNK inhibition studies, cells were incubated in cell cul-
ture medium for 15 hr in the presence of a JNK-specific inhibitor (SP600125,
Sigma, St. Louis, MO) or vehicle (DMSO). Cells were further incubated for 1 hr
in DMEM plus 0.5% BSA plus SP600125 or vehicle in 10 U/ml heparin, then
media were assayed. For RT-PCR, total RNA (1 mg) was treated with DNase
and reverse transcribed using Superscript II (Invitrogen, Carlsbad, CA) with
oligo-dT as primer. PCR was performed with the GeneAmp 7000 Sequence
Detection System using the TaqMan Universal Master Mix reagent kit
(Applied Biosystems, Foster City, CA). A negative control using RNA not
subjected to reverse transcription was included in each assay. The primer
and probe sets were as follows: mouse IRS-2: forward 50-CAGTCCCACATC
AGGCTTGAG-30, reverse 50-GGACTGCACGGATGACCTTAG-30, probe 50-
FAM-CCTTCAAGTCAGCCAGCCCCCTG-TAMRA-30; mouse LPL forward:
50-TTC ACT TTT CTG GGA CTG AGA ATG-30, reverse 50-GCC ACT GTG
CCG TAC AGA GA-30, probe 50-FAM-TCC AGC CAG GAT GCA ACA-TAM
RA-30, mouse EGR-1: forward 50-GCC TCG TGA GCA TGA CCA AT-30, re-
verse 50 GCA GAG GAA GAC GAT GAA GCA-30, probe 50-FAM-CTC CGA
CCT CTT CAT CCT CGG CG-BH-30. Sequence-specific amplification was
detected with an increasing fluorescence signal of FAM (reporter dye) during
the amplification cycle. Coamplification of the mRNA for the rodent GAPDH
control reagent (Applied Biosystems, Foster City, CA) or mouse ribosomal
protein L32 (forward 50-AAGCGAAACTGGCGGAAAC-30, reverse 50-GATC
TGGCCCTTGAACC-30, probe 50-HEX-CAGAGGCATTGACAACAGGGTG
CG-BH-30) was performed in the same tube for all samples. All assays were
run in triplicate. The results are expressed as relative expression of mRNA
normalized to GAPDH or L32 levels that were not affected by genotype.
Blood pressure determinations
Systolic and diastolic blood pressures were measured over several days in
conscious mice using a tail-cuff system (Kent Scientific, Litchfield, CT) as
described (Bernal-Mizrachi et al., 2003). Animals were habituated to the
blood pressure apparatus for several days before data were collected. Five
to eight measurements were recorded for each mouse at each of three daily
sessions. Results are presented as the mean of those measurements on
consecutive days.
Treatment of smooth muscle cells with antisense oligonucleotides
Smooth muscle cells were cultured from the aortas of apoE2/2 mice by the
explant technique as described (Weng et al., 2003). Smooth muscle cells
growing from the explants were passaged, expanded, and their identity
verified by staining with a fluorescent smooth muscle a-actin antibody (Vec-
tor Laboratories, Burlingame, CA). Morpholino antisense oligonucleotides
directed against mouse ATM and a control oligo were custom-made by
Gene Tools (Philomath, OR). The lissamine-tagged antisense oligo against
ATM had the following sequence: 50-GTGCTAGACTCATGGTTTAAGATTT-
30. Subconfluent mouse primary aortic smooth muscle cells were seeded
at a concentration of 13 106 per well in a 6-well tissue culture plate. After cul-
ture in serum-reduced DMEM (0.4% FBS) overnight, cells were incubated in
a 5 ml solution containing 1.4 mmol/L antisense ATM oligo or control oligo
with 0.56 mmol/L ethoxylated polyethylenimine for 3 hr and subsequently
switched to normal growth medium for at least 24 hr. Successful transfection
was confirmed by fluorescence microscopy and phospho-JNK and total JNK
were assayed 72 hr later using a cell-based ELISA kit.
Western blotting and ELISA
Western blotting was performed by standard techniques using the following
antibodies purchased from Cell Signaling (Beverly, MA): total Akt, phos-
phoAkt (Ser472 and Thr308), total p38 and phospho-p38 (Thr180/Tyr182),
phospho-ERK (Thr202/Tyr204), total JNK, phospho-JNK (Thr183/Tyr185),
total c-Jun, phospho-c-Jun (Ser63), total p53 and phospho-p53 (Ser18).CELL METABOLISM : NOVEMBER 2006
ATM and metabolic syndromeAnti-IRS-2 was purchased from Upstate Biotechnology (Lake Placid, NY).
Smooth muscle cells were assayed using a cell-based ELISA kit for phospho-
JNK from Activemotif (Carlsbad CA). Thioglycollate-elicited macrophages
were assayed using a phospho-JNK ELISA from Sigma (St. Louis, MO). Insulin
and adiponectin were assayed by ELISA using commercial reagents (Crystal
Chem, Downers Grove, IL; and Alpco Diagnostics, Salem, NH).
Hyperinsulinemic-euglycemic clamps
Clamp experiments were performed as described (Bernal-Mizrachi et al.,
2003; Tordjman et al., 2001). Double lumen catheters were placed and
3-[3H] glucose was infused to steady state. Regular human insulin was in-
fused at 10 mU/kg/min with 25% D-glucose to maintain blood glucose at
120 mg/dl for at least 90 min. The 3-[3H]glucose infusion was continued dur-
ing the clamp with labeled glucose included in the 25% D-glucose infusion to
match blood specific activity at steady state. The rate of appearance of glu-
cose (Ra), equal to glucose utilization (Rd) at steady state, was determined by
dividing the infusion rate of labeled glucose by specific activity. Endogenous
glucose production was calculated by subtracting the cold glucose infusion
rate from the clamp Rd.
Insulin signaling
IRS-2-associated PI 3-kinase activity was determined by immunoprecipitat-
ing IRS-2 from post-clamp liver protein extracts using an anti-IRS-2 antibody
(Upstate Biotechnology) and assessing PI 3-kinase activity of the IRS-2-
containing complex using an ELISA based assay (Echelon Biosciences
Inc.). Total and Ser473-phosphorylated Akt levels in whole-cell protein
extracts from mice after hyperinsulinemic clamp studies were measured by
immunoblotting using antibodies from Cell Signaling. For some studies,
mice were fasted overnight, injected with human insulin (10 mU/g), sacrificed
5 min later, then tissues dissected and snap frozen.
Bone marrow transplantation
Marrow was isolated from the femurs and tibias of 8-10 week old ATM+/+
apoE2/2 and ATM2/2apoE2/2 mice by flushing the bones with cold PBS.
Total bone marrow was washed, triturated using a 24 gauge needle (Benson
Dickson, Franklin Lakes, NJ), collected by centrifugation at 1250 rpm for 4
min and diluted with PBS. After lysis of erythrocytes using 0.05% sodium
azide, cells were counted to obtain a defined concentration of unfractionated
bone marrow. Recipient mice were lethally irradiated with 10 Gy from
a cesium 137 g cell irradiator. Within 6 hr after irradiation, recipients were
reconstituted with w5 3 106 donor marrow cells via a single injection. The
donor marrow was allowed to repopulate for 4 weeks after the transplanta-
tion. The resultant null allele was detected by genotyping of DNA from blood
(Qiagen Blood Kit, Germantown, MD). For estimating engraftment, total
bone marrow was isolated from the femurs and tibias from C57BL/
6-TgN(ACTbEGFP) (GFP) mice that were crossed onto an apoE null back-
ground. The marrow was processed as described and w5 3 106 cells of
unfractionated bone marrow in PBS were injected into a cohort of apoE
null mice in parallel to those described above. Four weeks later, blood was
drawn from the recipient mice, from GFP apoE null mice and from nonirradi-
ated apoE null mice. The degree of engraftment as assessed by FACS quan-
tification of the percentage of GFP in peripheral leucocytes as compared to
nontransplanted controls and the transgenic donor mice was 66%–92%.
Recipient mice were then placed on a Western-type diet for 8 weeks followed
by measurement of serum chemistries and determination of atherosclerosis
lesion extent by the aortic origin technique.
Statistical analyses
Statistical significance of differences was calculated using: the Student
unpaired t test for parametric data involving two groups, ANOVA for paramet-
ric data usually with Dunnett’s or Bonferroni post tests, the Mann-Whitney
test for nonparametric data involving two groups, and the Kruskal-Wallis
test for nonparametric data with Dunn’s post test.
Supplemental data
Supplemental Data include one table and six figures and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/4/5/
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